Screener
Rigel Pharmaceuticals RIGL Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | As of / March 31, 2026 | As of / December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Commitments | ||
| Stockholders’ equity: | ||
| Common stock | 18 | 18 |
| Additional paid-in capital | 1,414,394 | 1,414,322 |
| Accumulated other comprehensive (loss) income | (128) | 181 |
| Accumulated deficit | (1,014,387) | (1,023,041) |
| Total stockholders’ equity | 399,897 | 391,480 |
| Total liabilities and stockholders’ equity | $504,608 | $513,594 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's total equity?
- Rigel Pharmaceuticals (RIGL) reported total equity of $399.9M in Q1 2026.
- How has Rigel Pharmaceuticals's total equity changed year-over-year?
- Rigel Pharmaceuticals's total equity increased by 2053.8% year-over-year, from $18.57M to $399.9M.
- What is the long-term trend for Rigel Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's total equity has grown at a 63.0% compound annual growth rate (CAGR), from $34.03M to $391.48M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Rigel Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude